Lv1
90 积分 2024-07-23 加入
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
29天前
已完结
Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study
3个月前
已完结
Acute Kidney Injury in Patients with Cirrhosis
5个月前
已完结
Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis
7个月前
已完结
贝伐珠单抗致蛋白尿的潜在危险因素及保护因素分析
7个月前
已完结
Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities
7个月前
已完结
肺癌患者接受VEGF拮抗剂治疗出现肾损伤的影响因素研究
7个月前
已完结
Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis
7个月前
已完结
Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence
7个月前
已完结
Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors
7个月前
已完结
皖公网安备34019202002308
